Do analysts recommend BCTX or BDRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, BCTX or BDRX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A

Is BCTX or BDRX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Biodexa Pharmaceuticals N/A N/A N/A

Do analysts rate AYTU or BDRX?

Aytu BioPharma presently has a consensus target price of $9.83, indicating a potential upside of 349.01%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Aytu BioPharma is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, AYTU or BDRX?

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aytu BioPharma $66.38M 0.35 -$13.56M -$4.58 N/A Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A

Do analysts prefer ALLR or BDRX?

Allarity Therapeutics presently has a consensus price target of $10.25, indicating a potential upside of 688.46%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Allarity Therapeutics is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, ALLR or BDRX?

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Allarity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allarity Therapeutics $345K 59.95 -$11.23M -$0.72 N/A Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A

Is ALLR or BDRX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Biodexa Pharmaceuticals N/A N/A N/A

Do analysts prefer KZIA or BDRX?

Novogen currently has a consensus target price of $23.75, indicating a potential upside of 62.34%. Given Novogen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Novogen is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, KZIA or BDRX?

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 804.65 -$13.41M N/A N/A Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A

Is KZIA or BDRX more profitable?

Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Biodexa Pharmaceuticals N/A N/A N/A

Do analysts prefer NEUP or BDRX?

Neuphoria Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 367.71%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than Biodexa Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, NEUP or BDRX?

Neuphoria Therapeutics has higher earnings, but lower revenue than Biodexa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuphoria Therapeutics -$13.27K -1,829.23 -$370K -$11.06 N/A Biodexa Pharmaceuticals N/A N/A -$8.42M N/A N/A

Is NEUP or BDRX more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Biodexa Pharmaceuticals N/A N/A N/A

Biodexa Pharmaceuticals (BDRX) Competitors

$2.65 -0.01 (-0.38%)

Closing price 03:33 PM Eastern

Extended Trading

$2.61 -0.04 (-1.62%)

As of 06:49 PM Eastern

Compare

BDRX vs. BCTX, AYTU, ALLR, KZIA, and NEUP

Should you buy Biodexa Pharmaceuticals stock or one of its competitors? MarketBeat compares Biodexa Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biodexa Pharmaceuticals include Briacell Therap (BCTX), Aytu BioPharma (AYTU), Allarity Therapeutics (ALLR), Novogen (KZIA), and Neuphoria Therapeutics (NEUP). These companies are all part of the "pharmaceutical products" industry.

How does Biodexa Pharmaceuticals compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A

Biodexa Pharmaceuticals' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Biodexa Pharmaceuticals	N/A	N/A	N/A

Briacell Therap has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

In the previous week, Briacell Therap's average media sentiment score of 0.98 beat Biodexa Pharmaceuticals' score of 0.00 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Overall Sentiment
Briacell Therap	Positive
Biodexa Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Biodexa Pharmaceuticals beats Briacell Therap on 5 of the 7 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Biodexa Pharmaceuticals' return on equity of 0.00% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Biodexa Pharmaceuticals	N/A	N/A	N/A

In the previous week, Aytu BioPharma had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 1 mentions for Aytu BioPharma and 0 mentions for Biodexa Pharmaceuticals. Aytu BioPharma's average media sentiment score of 0.00 equaled Biodexa Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aytu BioPharma	Neutral
Biodexa Pharmaceuticals	Neutral

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A

Aytu BioPharma presently has a consensus target price of $9.83, indicating a potential upside of 349.01%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Aytu BioPharma is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aytu BioPharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

Summary

Aytu BioPharma beats Biodexa Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Allarity Therapeutics presently has a consensus price target of $10.25, indicating a potential upside of 688.46%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Allarity Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biodexa Pharmaceuticals' return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Biodexa Pharmaceuticals	N/A	N/A	N/A

In the previous week, Allarity Therapeutics had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 1 mentions for Allarity Therapeutics and 0 mentions for Biodexa Pharmaceuticals. Allarity Therapeutics' average media sentiment score of 0.50 beat Biodexa Pharmaceuticals' score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allarity Therapeutics	Positive
Biodexa Pharmaceuticals	Neutral

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Allarity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$345K	59.95	-$11.23M	-$0.72	N/A
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A

Allarity Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Summary

Allarity Therapeutics and Biodexa Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Novogen?

Novogen (NASDAQ:KZIA) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Biodexa Pharmaceuticals	N/A	N/A	N/A

Novogen currently has a consensus target price of $23.75, indicating a potential upside of 62.34%. Given Novogen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Novogen is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Novogen had 1 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 1 mentions for Novogen and 0 mentions for Biodexa Pharmaceuticals. Novogen's average media sentiment score of 0.00 equaled Biodexa Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Novogen	Neutral
Biodexa Pharmaceuticals	Neutral

Novogen has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

30.9% of Novogen shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Biodexa Pharmaceuticals has lower revenue, but higher earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	804.65	-$13.41M	N/A	N/A
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A

Summary

Novogen beats Biodexa Pharmaceuticals on 8 of the 9 factors compared between the two stocks.

How does Biodexa Pharmaceuticals compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Neuphoria Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Biodexa Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Biodexa Pharmaceuticals' return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Biodexa Pharmaceuticals	N/A	N/A	N/A

In the previous week, Neuphoria Therapeutics' average media sentiment score of 0.00 equaled Biodexa Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Biodexa Pharmaceuticals	Neutral

Neuphoria Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 367.71%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than Biodexa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Neuphoria Therapeutics has higher earnings, but lower revenue than Biodexa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	-$13.27K	-1,829.23	-$370K	-$11.06	N/A
Biodexa Pharmaceuticals	N/A	N/A	-$8.42M	N/A	N/A

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Neuphoria Therapeutics and Biodexa Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

Get Biodexa Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDRX vs. The Competition

Export

Metric	Biodexa Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.29M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	N/A	20.68	25.17	24.00
Price / Sales	N/A	336.69	553.76	120.62
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.02	8.26	10.76	6.41
Net Income	-$8.42M	$23.91M	$3.56B	$337.14M
7 Day Performance	-11.96%	3.05%	1.37%	-0.48%
1 Month Performance	-19.21%	2.40%	0.81%	0.49%
1 Year Performance	-94.25%	56.35%	30.53%	28.16%

Biodexa Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDRX Biodexa Pharmaceuticals	0.5754 of 5 stars	$2.65 -0.4%	N/A	-94.0%	$5.29M	N/A	N/A	20
BCTX Briacell Therap	0.4889 of 5 stars	$2.83 +3.3%	N/A	-89.6%	$23.84M	N/A	N/A	8
AYTU Aytu BioPharma	2.7082 of 5 stars	$2.08 -5.5%	$9.83 +372.8%	+13.1%	$23.61M	$56.60M	N/A	160	High Trading Volume
ALLR Allarity Therapeutics	2.4136 of 5 stars	$1.43 -3.4%	$10.25 +616.8%	+46.7%	$23.55M	$320K	N/A	10
KZIA Novogen	1.6541 of 5 stars	$13.77 -2.2%	$23.75 +72.5%	+117.0%	$23.28M	$30K	N/A	12

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDRX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. BCTX, AYTU, ALLR, KZIA, and NEUP

How does Biodexa Pharmaceuticals compare to Briacell Therap?

Summary

How does Biodexa Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Biodexa Pharmaceuticals compare to Allarity Therapeutics?

Summary

How does Biodexa Pharmaceuticals compare to Novogen?

Summary

How does Biodexa Pharmaceuticals compare to Neuphoria Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodexa Pharmaceuticals (BDRX) Competitors

BDRX vs. BCTX, AYTU, ALLR, KZIA, and NEUP

How does Biodexa Pharmaceuticals compare to Briacell Therap?

Which has preferable earnings and valuation, BCTX or BDRX?

Is BCTX or BDRX more profitable?

Which has more volatility & risk, BCTX or BDRX?

Does the media favor BCTX or BDRX?

Do analysts recommend BCTX or BDRX?

Do insiders & institutionals believe in BCTX or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to Aytu BioPharma?

Is AYTU or BDRX more profitable?

Does the media favor AYTU or BDRX?

Which has stronger valuation and earnings, AYTU or BDRX?

Do analysts rate AYTU or BDRX?

Do institutionals & insiders have more ownership in AYTU or BDRX?

Which has more volatility & risk, AYTU or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to Allarity Therapeutics?

Do analysts prefer ALLR or BDRX?

Is ALLR or BDRX more profitable?

Does the media prefer ALLR or BDRX?

Do insiders & institutionals have more ownership in ALLR or BDRX?

Which has stronger earnings and valuation, ALLR or BDRX?

Which has more volatility & risk, ALLR or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to Novogen?

Is KZIA or BDRX more profitable?

Do analysts prefer KZIA or BDRX?

Does the media prefer KZIA or BDRX?

Which has more risk and volatility, KZIA or BDRX?

Do insiders and institutionals have more ownership in KZIA or BDRX?

Which has better valuation and earnings, KZIA or BDRX?

Summary

How does Biodexa Pharmaceuticals compare to Neuphoria Therapeutics?

Which has more risk & volatility, NEUP or BDRX?

Is NEUP or BDRX more profitable?

Does the media favor NEUP or BDRX?

Do analysts prefer NEUP or BDRX?

Which has preferable valuation and earnings, NEUP or BDRX?

Do insiders & institutionals believe in NEUP or BDRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX vs. The Competition

Biodexa Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools